|
gptkbp:instanceOf
|
gptkb:research_institute
|
|
gptkbp:affiliatedWith
|
gptkb:University_of_Oxford
|
|
gptkbp:collaboratedWith
|
gptkb:Janssen
gptkb:World_Health_Organization
gptkb:AstraZeneca
|
|
gptkbp:country
|
gptkb:United_Kingdom
|
|
gptkbp:director
|
gptkb:Professor_Andrew_Pollard
|
|
gptkbp:established
|
1994
|
|
gptkbp:focusesOn
|
clinical trials
vaccine research
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Oxford Vaccine Group
|
|
gptkbp:locatedIn
|
gptkb:Oxford,_England
|
|
gptkbp:notableProject
|
gptkb:Oxford–AstraZeneca_COVID-19_vaccine
|
|
gptkbp:parentOrganization
|
gptkb:Department_of_Paediatrics,_University_of_Oxford
|
|
gptkbp:studies
|
gptkb:COVID-19
gptkb:RSV_(respiratory_syncytial_virus)
influenza
meningitis
typhoid
|
|
gptkbp:website
|
https://www.ovg.ox.ac.uk/
|
|
gptkbp:bfsParent
|
gptkb:Jenner_Institute
|
|
gptkbp:bfsLayer
|
7
|